# Tenax Therapeutics, Inc.: overview TENX · Nasdaq · CIK 34956 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tenx.md) · [Financials](/companies/tenx/financials.md) · [Filings](/companies/tenx/filings.md) · [Insiders](/companies/tenx/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-327455.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-327455). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | [0.0](/filings/0000950170-25-071395.md) | [0.0 d](/filings/0000950170-25-108063.md) | [0.0 d](/filings/0001193125-25-277793.md) | [0.0 d](/filings/0001193125-26-099393.md) | [0.0](/filings/0001193125-26-219383.md) | [0.0 d](/filings/0001193125-26-327455.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.19)](/filings/0001193125-25-277793.md) | not reported | [(0.28)](/filings/0001193125-26-219383.md) | [(0.27)](/filings/0001193125-26-327455.md) | [(0.40)](/filings/0001193125-25-277793.md) | not reported | [(0.35)](/filings/0001193125-26-219383.md) | [(0.35)](/filings/0001193125-26-327455.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-044398.md) | [0.0](/filings/0001193125-26-099393.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.58)](/filings/0001654954-22-004036.md) | not reported | [(31.04)](/filings/0000950170-25-044398.md) | [(1.15)](/filings/0001193125-26-099393.md) | [(1.34)](/filings/0001193125-26-099393.md) | | Free cash flow | $m | [(10.9)](/filings/0001654954-23-003945.md) | [(11.4)](/filings/0001654954-24-003827.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tenx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $57.4m | 3,942,373 | | Added +3,619,773 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $36.4m | 2,500,000 | | Added +2,291,667 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $29.1m | 1,815,474 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $25.1m | 1,727,988 | | Added +1,711,011 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $24.7m | 1,700,000 | | Added +252,218 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.7m | 1,147,121 | | Added +883,700 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $12.7m | 876,230 | | Added +342,341 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $11.5m | 787,600 | | Reduced −230,000 | | [Candriam S.C.A.](/funds/1537014.md) | 2026-06-30 | $10.9m | 749,588 | | New +749,588 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $10.6m | 728,561 | | Added +576,045 | ## Recent filings [All 851 filings](/companies/tenx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 16:15 ET | [8-K](/filings/0001193125-26-417939.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-417939 | | 2026-09-09 | 08:00 ET | [8-K](/filings/0001193125-26-385910.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385910 | | 2026-08-10 | 07:19 ET | [8-K](/filings/0001193125-26-341236.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-341236 | | 2026-07-31 | 16:15 ET | [SCHEDULE 13D/A](/filings/0001193125-26-328603.md) | Ownership report, active investor, amended | 0001193125-26-328603 | | 2026-07-31 | 11:25 ET | [10-Q](/filings/0001193125-26-327455.md) | Quarterly report, period 2026-06-30 | 0001193125-26-327455 | | 2026-07-31 | 07:23 ET | [8-K](/filings/0001193125-26-326784.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-326784 | | 2026-07-02 | 08:00 ET | [8-K](/filings/0001193125-26-293485.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-293485 | | 2026-06-30 | 16:30 ET | [8-K](/filings/0001193125-26-290661.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-290661 | | 2026-06-29 | 16:40 ET | [8-K](/filings/0001193125-26-288600.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-288600 | | 2026-06-04 | 16:10 ET | [8-K](/filings/0001193125-26-257400.md) | 5.07 Shareholder vote results | 0001193125-26-257400 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-099393.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/777fe72e-77de-4522-a91c-b43ff28d44b5) ## About the filer - CIK: 34956 - Tickers: TENX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.